How is a technology-based intangible asset identified and valued in a business combination?

Question

AcadiFi · Accepted Answer

Technology-based intangibles — including patented technology, proprietary software, trade secrets, and databases — are among the most common identifiable assets in technology and pharma acquisitions. Valuation depends on whether the technology is licensed or used internally. **Identification Criteria** Technology meets the identifiability standard through: - **Contractual/legal rights:** Patents, copyrights, registered software - **Separability:** Proprietary software or databases that could theoretically be licensed or sold **Valuation Methods by Scenario** | Scenario | Primary Method | When Used | |---|---|---| | Technology is licensed externally | Relief-from-royalty | Royalty rate observable from comparable licenses | | Technology used internally, generates direct revenue | Multi-period excess earnings (MPEEM) | When technology is the primary value driver | | Technology supports other assets | Replacement cost (less obsolescence) | When technology is a contributory asset | **Worked Example — Quorum Data acquires Helix AI (proprietary ML platform):** Helix's machine learning platform is used internally to deliver analytics services. No external licensing exists. The PPA team uses a **replacement cost less obsolescence** approach: | Component | Amount | |---|---| | Estimated development labor (18 engineers x 2.5 years x $185K) | $8,325,000 | | Infrastructure & tooling costs during development | $1,200,000 | | Developer's profit (15% of total cost) | $1,428,750 | | Gross replacement cost | $10,953,750 | | Less: functional obsolescence (20% — newer frameworks available) | ($2,190,750) | | Less: economic obsolescence (10% — market contraction in segment) | ($876,300) | | **Fair value of technology intangible** | **$7,886,700** | **Useful Life Determination** Technology intangibles are almost always **finite-lived**. The useful life considers: \`\`\`mermaid flowchart LR A["Technology
Useful Life"] --> B["Patent Term
(Legal Life)"] A --> C["Product Lifecycle
(Economic Life)"] A --> D["Replacement
Cycle Plans"] A --> E["Competitive
Landscape"] B --> F["Use Shorter of
Legal & Economic"] C --> F D --> F E --> F \`\`\` Typical ranges: Software 3-7 years, Patented pharma 8-15 years (tied to patent expiry), Industrial processes 5-10 years. **Key Points:** 1. Developed technology (existing products) is separated from in-process R&D (IPR&D), which has its own rules. 2. IPR&D acquired in a business combination is capitalized as an indefinite-lived intangible until the project completes or is abandoned. 3. Technology amortization reduces post-acquisition EBIT — analysts adjust for this in normalized earnings. 4. Obsolescence deductions in the cost approach directly reduce the intangible value and increase goodwill. Our CFA Level II modules include technology PPA case studies across multiple industries.

How is a technology-based intangible asset identified and valued in a business combination?

Master Level II with our CFA Course

Related Questions

Practice Questions